Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold.

Abstract

OBJECTIVES:

To evaluate safety and efficacy of the everolimus-eluting bioresorbable scaffold (BVS) in patients with ST-segment elevation myocardial infarction (STEMI).

BACKGROUND:

According to the current guidelines, drug-eluting stents are the treatment of choice in patients with STEMI. BVS represents a new technology capable to restore the native vessel vasomotion and potentially avoiding long-term limitations such as stent thrombosis.

METHODS:

From October 2012 to May 2013, patients with evidence of STEMI eligible for BVS implantation were included in this study. Exclusion criteria were not defined.

RESULTS:

A total of 25 patients, respectively 31 lesions, were treated. Procedural success was achieved in 97%. Two major adverse cardiac events occurred during hospitalization and follow-up: one patient with cardiogenic shock at the index procedure subsequently died. One patient suffered from instable angina with need for interventional revascularization of a previously untreated vessel. One target vessel failure as a consequence of an intra-procedural dissection was seen. However, no target lesion failure was noted. During 132.7 ± 68.7 days of follow-up none of the patients died.

CONCLUSION:

Our findings suggest that implantation of BVS in STEMI patients is feasible in this small cohort of highly selected patients. Further evaluation in randomized-controlled trials is needed.

• Authors: Jens Wiebe, Helge Möllmann, Astrid Most, Oliver Dörr, Kay Weipert, Johannes Rixe, Christoph Liebetrau, Albrecht Elsässer, Stephan Achenbach, Christian Hamm, Holger Nef
• Journal: Clinical research in cardiology : official journal of the German Cardiac Society (Clin Res Cardiol) Vol. 103 Issue 2 Pg. 141-8 (Feb 2014) ISSN: 1861-0692 [Electronic] Germany
• PMID: 24136291 (Publication Type: Journal Article, Observational Study)

Chemical References

• Cardiovascular Agents
• Coated Materials, Biocompatible
• Everolimus
• Sirolimus

Topics

• Absorbable Implants
• Aged
• Cardiovascular Agents (administration & dosage)
• Coated Materials, Biocompatible
• Coronary Angiography
• Everolimus
• Feasibility Studies
• Female
• Humans
• Male
• Middle Aged
• Myocardial Infarction (diagnosis, therapy)
• Percutaneous Coronary Intervention (adverse effects, instrumentation)
• Prosthesis Design
• Sirolimus (administration & dosage, analogs & derivatives)
• Time Factors
• Tissue Scaffolds
• Tomography, Optical Coherence
• Treatment Outcome